Becton, Dickinson and Company Announces Executive Changes
January 06, 2023 at 06:50 am EST
Share
Becton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics and
compliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. In
addition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs and
Regulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
